How liver function affects the drug velzatinib
Part of Cancer, Digestive system clinical trials.
This study tests how the body processes the drug velzatinib in people with different levels of liver function, compared to those with healthy livers. The results may help doctors determine the right dose for people with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your liver function must be stable, meaning it hasn't worsened in the last 14 days.
- If you have liver disease, you must have a certain level of liver function (classified as mild, moderate, or severe).
- You must not have had a liver transplant or a transjugular intrahepatic portosystemic shunt (TIPS).
- If you have hepatitis B or C, certain viral levels must be low or undetectable.
- You must not drink more than 14 units of alcohol per week on average.
- Your blood pressure and heart rate must be within a specific range.
- You must not have significant heart problems like irregular heart rhythms or heart block.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a medicine called velzatinib affects people with moderate or severe kidney problems compared to those with normal kidney function. The goal is to see if the medicine is safe and how it is processed by the body.
This study checks if stomach acid medicine and another drug affect how the body handles a new investigational drug. It helps researchers understand dosing for future patients.
This study tests how the drug Vepdegestrant is processed by people with different levels of liver function. It aims to understand if liver problems change how the drug works, which can help doctors give the right dose.
This study tests a new drug called sevabertinib to see if it changes how the body handles metformin, a common diabetes medicine. It is for healthy adults and will help researchers understand if the two drugs can be taken together safely.
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
This study looks at how the body handles the study drug vorolanib (taken as a tablet) when your liver is impaired. It might help doctors understand the right dose for people with liver problems, and it may also benefit those who are newly diagnosed or exploring treatment options.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.